Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) was the target of a large decline in short interest in December. As of December 29th, there was short interest totalling 4,199,485 shares, a decline of 12.0% from the December 15th total of 4,773,699 shares. Based on an average daily volume of 539,880 shares, the short-interest ratio is currently 7.8 days. Currently, 2.7% of the company’s stock are sold short.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) opened at $0.40 on Tuesday. Navidea Biopharmaceuticals has a 1-year low of $0.29 and a 1-year high of $0.85. The firm has a market capitalization of $63.72, a PE ratio of -5.71 and a beta of -0.63.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter. Navidea Biopharmaceuticals had a negative net margin of 688.85% and a negative return on equity of 38.60%. The business had revenue of $0.22 million for the quarter.

An institutional investor recently raised its position in Navidea Biopharmaceuticals stock. Vanguard Group Inc. increased its holdings in shares of Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) by 1.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,887,743 shares of the biopharmaceutical company’s stock after purchasing an additional 80,499 shares during the period. Vanguard Group Inc. owned approximately 3.02% of Navidea Biopharmaceuticals worth $2,492,000 at the end of the most recent quarter.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease.

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.